Acute liver failure differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(29 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Acute liver failure}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Acute_liver_failure]]
{{CMG}} {{AE}}
{{CMG}} {{AE}} {{HS}}
 
 
==Overview==
==Overview==
There are some diseases or conditions which have a similar presentation to acute liver failure. These include [[tyrosenemia]], [[fructose intolerance]], being affected by the toxin from [[bacillus cereus]], and the [[HELLP syndrome]] of pregnancy.
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of [[jaundice]], [[coagulopathy]], and [[encephalopathy]]. The differentials include [[acute hepatitis]], [[cholestatic jaundice]], and [[Hemolytic|hemolytic jaundice]]. The common causes of [[acute hepatitis]] causing acute liver failure include [[acetaminophen toxicity]], [[viral hepatitis]], [[alcoholic hepatitis]], [[autoimmune hepatitis]], [[acute fatty liver of pregnancy]], [[Wilson's disease]], [[ischemic hepatitis]] and hepatic congestion due to [[right heart failure]] and [[Budd-Chiari syndrome|Budd–chiari syndrome]].


==Differentiating Acute Liver Failure from other Diseases==
==Differentiating Acute Liver Failure from other Diseases==
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy.
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of [[jaundice]], [[coagulopathy]], and [[encephalopathy]].<ref name="pmid17370334">{{cite journal| author=Escorsell A, Mas A, de la Mata M, Spanish Group for the Study of Acute Liver Failure| title=Acute liver failure in Spain: analysis of 267 cases. | journal=Liver Transpl | year= 2007 | volume= 13 | issue= 10 | pages= 1389-95 | pmid=17370334 | doi=10.1002/lt.21119 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17370334  }} </ref><ref name="pmid17608778">{{cite journal| author=Bower WA, Johns M, Margolis HS, Williams IT, Bell BP| title=Population-based surveillance for acute liver failure. | journal=Am J Gastroenterol | year= 2007 | volume= 102 | issue= 11 | pages= 2459-63 | pmid=17608778 | doi=10.1111/j.1572-0241.2007.01388.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17608778  }} </ref><ref name="pmid20196116">{{cite journal| author=Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD et al.| title=Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. | journal=Hepatology | year= 2010 | volume= 51 | issue= 5 | pages= 1665-74 | pmid=20196116 | doi=10.1002/hep.23534 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20196116  }} </ref><ref name="pmid22213561">{{cite journal| author=Lee WM, Stravitz RT, Larson AM| title=Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. | journal=Hepatology | year= 2012 | volume= 55 | issue= 3 | pages= 965-7 | pmid=22213561 | doi=10.1002/hep.25551 | pmc=3378702 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22213561  }} </ref>
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
| valign="top" |
| valign="top" |
Line 18: Line 16:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Acute hepatits
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Acute hepatits
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Jaundice and coagulopathy may be present.
* [[Jaundice]] and [[coagulopathy]] may be present.


* Severe acute hepatitis is followed very closely as it has a potential to develop into acute or subacute hepatic failure.
* Severe [[acute hepatitis]] is followed very closely as it has a potential to develop into acute or subacute hepatic failure.
 
* Acute hepatitis would not be considered acute liver failure unless [[hepatic encephalopathy]] is present.
* Common causes are [[viral hepatitis]], [[acetaminophen overdose]], [[alcoholic hepatitis]], [[autoimmune hepatitis]] and [[Metabolic disorder|metabolic disorders]] such as [[Wilson's disease]] and [[hemochromatosis]].


* Acute hepatitis would not be considered acute liver failure unless hepatic encephalopathy is present.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Hepatic encephalopathy is absent.
* [[Hepatic encephalopathy]] is absent.
* Grades of hepatic encephalopathy are:
* Grades of hepatic encephalopathy are:
** Grade 1
** Grade 1: Trivial lack of awareness; [[euphoria]] or [[anxiety]]; shortened attention span.
** Grade 2
** Grade 2: Lethargy or [[apathy]]; minimal [[disorientation]] for time or place; subtle personality change; inappropriate behavior; impaired performance of subtraction.
** Grade 3
** Grade 3:  [[Somnolence]] to semi-stupor, but responsive to verbal stimuli; [[confusion]]; gross disorientation.
** Grade 4
** Grade 4:  [[Coma]] (unresponsive to verbal or noxious stimuli).
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Cholestasis
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Cholestasis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] also observed in [disease name].
* [[Jaundice]] can be seen due to intra or extrahepatic [[biliary obstruction]], as well as intrahepatic [[cholestasis]] due to conditions like drug-induced liver injury.
 
* The absence of [[hepatic encephalopathy]] and [[coagulopathy]] will differentiate it from acute liver failure.
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] that distinguish it from [disease name].
* Absence of [[Hepatic encephalopathy|hepatic encephalopathy.]]
* [[INR|Normal PT/INR.]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Hemolysis
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Hemolysis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] also observed in [disease name].
* May have [[jaundice]] with increased ([[Unconjugated bilirubin|unconjugated]]) indirect serum [[bilirubin]].
 
* Liver dysfunction may not be present. So, [[coagulopathy]] and [[hepatic encephalopathy]] would not be there.
* Common examples are [[hemolytic anemias]].
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] that distinguish it from [disease name].
* Absence of [[Hepatic encephalopathy|hepatic encephalopathy.]]
* Normal [[Prothrombin time|PT/INR]].
* Abnormal [[Peripheral blood smear|peripheral blood smear.]]
|}   
|}   
    
    
Line 107: Line 115:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N
Line 120: Line 128:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N
Line 166: Line 174:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Dilated ducts on sono
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Dilated ducts on sono
Line 180: Line 188:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |HAV- AB
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |HAV- AB
Line 194: Line 202:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Positive serology
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Positive serology
Line 208: Line 216:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑?
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |AMA positive
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |AMA positive
Line 222: Line 230:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑?
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Beading on MRCP  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Beading on MRCP  

Latest revision as of 21:40, 8 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The differentials include acute hepatitis, cholestatic jaundice, and hemolytic jaundice. The common causes of acute hepatitis causing acute liver failure include acetaminophen toxicity, viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, acute fatty liver of pregnancy, Wilson's disease, ischemic hepatitis and hepatic congestion due to right heart failure and Budd–chiari syndrome.

Differentiating Acute Liver Failure from other Diseases

Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy.[1][2][3][4]

Condition Differentiating signs and symtoms Differentiating Tests
Acute hepatits
  • Severe acute hepatitis is followed very closely as it has a potential to develop into acute or subacute hepatic failure.
  • Hepatic encephalopathy is absent.
  • Grades of hepatic encephalopathy are:
    • Grade 1: Trivial lack of awareness; euphoria or anxiety; shortened attention span.
    • Grade 2: Lethargy or apathy; minimal disorientation for time or place; subtle personality change; inappropriate behavior; impaired performance of subtraction.
    • Grade 3:  Somnolence to semi-stupor, but responsive to verbal stimuli; confusion; gross disorientation.
    • Grade 4:  Coma (unresponsive to verbal or noxious stimuli).
Cholestasis
Hemolysis

Abbreviations: RUQ= Right upper quadrant of the abdomen, LFT= Liver function test, SIRS= Systemic inflammatory response syndrome, ERCP= Endoscopic retrograde cholangiopancreatography, N= Normal, AMA= Anti mitochondrial antibodies, LDH= Lactate dehydrogenase, GI= Gastrointestinal, CT= Computed tomography

Classification of jaundice based on etiology Disease History and clinical manifestations Diagnosis
Lab Findings Other blood tests Other diagnostic
Family history Fever RUQ Pain Pruritis AST ALT ALK BLR Indirect BLR Direct Viral serology
Jaundice Hepatocellular Jaundice Hemochromatosis + - -/+ - ↑/N ↑/N N - Ferritin ↑ Liver biopsy
Wilson's disease + - -/+ - N ↑/N N - Serum cerulloplasmin ↑ Liver biopsy
Viral hepatitis - -/+ - - ↑↑ N ↑/N N + Specific viral antibody for each type -
Alcoholic hepatitis - - - - ↑↑ N ↑/N N - - -
Drug induced hepatitis - -/+ - - N ↑/N N - - -
Autoimmune hepatitis -/+ - - -/+ N ↑/N N - Anti-LKM antibody Liver biopsy
Cholestatic Jaundice Common bile duct stone -/+ - + + N N N - Dilated ducts on sono CT/ERCP
Hepatitis A cholestatic type - -/+ + + N N N + HAV- AB Abdominal ultrasound
EBV / CMV hepatitis - -/+ + + N N N + Positive serology
Primary biliary cirrhosis -/+ - -/+ + N/↑ N/↑ ↑? - AMA positive Liver biopsy
Primary sclerosing cholangitis -/+ - -/+ + N/↑ N/↑ ↑? - Beading on MRCP Liver biopsy
Isolated Jaundice Crigler-Najjar type 2 + - - - N N N N - Genetic testing
Gilbert + - - - N N N N - Genetic testing
Rotor syndrome + - - - N N N N - Genetic testing Liver biopsy
Dubin-Johnson syndrome + - - - N N N N - Genetic testing Liver biopsy
Hereditory spherocytosis + - -/+ - N N N N - Genetic testing Osmotic fragility
G6PD deficiency + - - - N N N N - Genetic testing
Thalassemia + - - - N N N N - Genetic testing
Sickle cell disease + - - - N N N N - Genetic testing
Paroxismal nocturnal hemoglobinoria - - - - N N N N - Flocytometery
Immune hemolysis - -/+ - - N N N N - Autoantibodies
Hematoma - -/+ - - N N N N - Anemia Truma or surgery in history

References

  1. Escorsell A, Mas A, de la Mata M, Spanish Group for the Study of Acute Liver Failure (2007). "Acute liver failure in Spain: analysis of 267 cases". Liver Transpl. 13 (10): 1389–95. doi:10.1002/lt.21119. PMID 17370334.
  2. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007). "Population-based surveillance for acute liver failure". Am J Gastroenterol. 102 (11): 2459–63. doi:10.1111/j.1572-0241.2007.01388.x. PMID 17608778.
  3. Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD; et al. (2010). "Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome". Hepatology. 51 (5): 1665–74. doi:10.1002/hep.23534. PMID 20196116.
  4. Lee WM, Stravitz RT, Larson AM (2012). "Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011". Hepatology. 55 (3): 965–7. doi:10.1002/hep.25551. PMC 3378702. PMID 22213561.

Template:WH Template:WS